StockData
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. (RDHL) stock

RDHLNasdaqPharmaceutical Preparations
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 27, 2026Score 0/30
$0.35−0.01 (-2.91%)

Close on Nov 17, 2026Market cap $1.78MP/E –Yield –

RedHill Biopharma pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

RedHill Biopharma's pe ratio was 0.0× on Feb 28, 2025, against 2.4× a year earlier. Over the last 2 years it ranged from 0.0× to 4.9×, with a median of 2.4×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Feb 28, 20250.0×−0.0
2024Dec 31, 20240.1×−2.4
2020Feb 28, 20202.4×−1.1
2019Dec 31, 20193.6×–

More RedHill Biopharma figures

See a number that looks wrong?